Treatment of diabetic retinopathy using endothelin receptor antagonists
AssigneePerfuse Therapeutics, Inc.
InventorsSevgi Gurkan, David Floyd
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the discovery that certain diseases of the eye that profoundly affect the human visual system and, as a result, quality of life, may be treated using Edonentan or A-182086. Edonentan or A-182086 can be used alone or in combination with an intra-ocular pressure (IOP) reducing agent, a neuroprotective agent, an anti-VEGF agent, or all, for example. Using Edonentan or A-182086, alone or in combination with an additional agent, provides increased perfusion to the retina in certain diseases and reduces damage to retinal cells.
Claims13
1-24. (canceled)
A method of treating diabetic retinopathy in a patient in need thereof, the method comprising a step of:
- injecting an intravitreal implant composition to the back of the eye of the patient every 3 to 6 months, wherein the intravitreal implant composition comprises between about 100 μg and about 500 μg of Edonentan.
A method of treating diabetic retinopathy in a patient in need thereof, comprising injecting a therapeutically effective amount of an ophthalmic preparation to the back of the eye of the patient every 3 to 6 months, wherein each ophthalmic preparation comprises Edonentan.
A method of treating diabetic retinopathy in a subject in need thereof, comprising:
- injecting a composition comprising a therapeutically effective amount of Edonentan into an optical tissue of said subject having diabetic retinopathy.
Dependencies are inferred from the claim text.